Skip to main content

Glenmark's antiviral combination for moderate Covid-19 shows no clinical benefit

By Unknown

Glenmark Pharmaceuticals Ltd on Friday said addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in moderate Covid-19 patients. Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment, the trial did not meet key end-points, the company said.

The trial's findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes, Monika Tandon, senior vice president & head, Clinical Development, Global Specialty/Branded Portfolio at the company, said in a statement , adding that favipiravir alone remains the effective choice for mild to moderate COVID-19 infection.

Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014, while Umifenovir is licensed as a treatment for some types of flu infections in Russia and China.

Fujifilm last month said a late-stage study of Avigan showed it reduced recovery times for COVID-19 patients with non-severe symptoms.

Mumbai-based Glenmark in July said its version of Favipiravir alone showed promise in a late-stage study of patients with mild to moderate coronavirus infection.

This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir.

This second study titled the FAITH trial evaluated the possible superiority of the combination’s efficacy against Favipiravir monotherapy.

The FAITH study enrolled a total of 158 hospitalized patients with moderate COVID-19 in India.

In June 2020, Glenmark became the first company in India to receive manufacturing and marketing approval for FabiFlu as part of accelerated approval process, considering the emergency situation of the COVID-19 outbreak in the country.

Comments

Post a Comment

Popular posts from this blog

Increased risks of drop out for women and girls : CoronaVirus Updates

By Unknown
The total number of children not returning to their education after the school closures is likely to be significant. The pandemic also risks jeopardizing some of the gains made since 2001 in re-building women and girls’ education following the Taliban regime.  The COVID-19 pandemic is creating additional barriers due to risks—and students’ and parents’ anxiety about risks—associated with children returning to classrooms that are cramped, with no capacity for distancing, often cold, damp and poorly ventilated during the country’s severe winters, and have no or poor hygiene and clean water facilities. The COVID-19 pandemic is likely to drive many women and girls out of education permanently. School closures due to COVID-19, resulting increases in caregiving responsibilities for women and girls, and increases in poverty and unemployment will all make it harder for women and girls to study.  These factors combine in harmful ways with pre-existing discriminatory gender norms, o...
Post a Comment
Read more

No significant benefit of Umifenovir in COVID-19 treatment: Glenmark

By Unknown
Drug firm  Glenmark Pharmaceuticals  on Friday said the addition of  antiviral Umifenovir  did not demonstrate any significant clinical benefit over  Favipiravir  alone in  moderate COVID-19 patients .  The  clinical study  evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy, Glenmark said in a statement. As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir, it added. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir, Glenmark said. "These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-1...
Post a Comment
Read more